Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>Imunon, Inc. (IMNN) is finishing preparations to initiate a Phase 3 clinical trial of its lead development compound, IMNN-001, in the treatment of advanced ovarian cancer.</li><li>In support of this, the company recently announced a positive Type C Chemistry, Manufacturing, and Controls (CMC) meeting in which the agency agreed the company's potency assay is acceptable for the Phase 3 trial and use in a commercial setting.</li><li>This follows the company's prior announcement in which it had reached alignment with the FDA on its proposed plan for the Phase 3 trial, including the overall trial design, the target patient population, the treatment schedule, and the primary endpoint.</li></ul>

Imunon, Inc. (IMNN) is finishing preparations to initiate a Phase 3 clinical trial of its lead development compound, IMNN-001, in the treatment of advanced ovarian cancer.In support of this, the company recently announced a positive Type C Chemistry, Manufacturing, and Controls (CMC) meeting in which the agency agreed the company's potency assay is acceptable for the Phase 3 trial and use in a commercial setting.This follows the company's prior announcement in which it had reached alignment with the FDA on its proposed plan for the Phase 3 trial, including the overall trial design, the target patient population, the treatment schedule, and the primary endpoint.

IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25 